Literature DB >> 31772029

Cardiac valve involvement in ADAR-related type I interferonopathy.

Yanick Crow1,2, Nandaki Keshavan3,4, Jacques Patrick Barbet5, Geanina Bercu6, Vincent Bondet7, Charlotte Boussard8, Nathalie Dedieu9, Darragh Duffy7, Marie Hully10, Alessandro Giardini9, Cyril Gitiaux10, Gillian Inara Rice11, Luis Seabra1, Brigitte Bader-Meunier8,12, Shamima Rahman13,4.   

Abstract

BACKGROUND: Adenosine deaminases acting on RNA (ADAR) mutations cause a spectrum of neurological phenotypes ranging from severe encephalopathy (Aicardi-Goutières syndrome) to isolated spastic paraplegia and are associated with enhanced type I interferon signalling. In children, non-neurological involvement in the type I interferonopathies includes autoimmune and rheumatological phenomena, with calcifying cardiac valve disease only previously reported in the context of MDA5 gain-of-function.
RESULTS: We describe three patients with biallelic ADAR mutations who developed calcifying cardiac valvular disease in late childhood (9.5-14 years). Echocardiography revealed progressive calcification of the valvular leaflets resulting in valvular stenosis and incompetence. Two patients became symptomatic with biventricular failure after 5-6.5 years. In one case, disease progressed to severe cardiac failure despite maximal medical management, with death occurring at 17 years. Another child received mechanical mitral and aortic valve replacement at 16 years with good postoperative outcome. Histological examination of the affected valves showed fibrosis and calcification.
CONCLUSIONS: Type I interferonopathies of differing genetic aetiology demonstrate an overlapping phenotypic spectrum which includes calcifying cardiac valvular disease. Individuals with ADAR-related type I interferonopathy may develop childhood-onset multivalvular stenosis and incompetence which can progress insidiously to symptomatic, and ultimately fatal, cardiac failure. Regular surveillance echocardiograms are recommended to detect valvular disease early. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  cardiovascular medicine; clinical genetics; immunology (including allergy); metabolic disorders

Mesh:

Substances:

Year:  2019        PMID: 31772029     DOI: 10.1136/jmedgenet-2019-106457

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  4 in total

1.  Case Report: Aicardi-Goutières Syndrome Type 6 and Dyschromatosis Symmetrica Hereditaria With Congenital Heart Disease and Mitral Valve Calcification - Phenotypic Variants Caused by Adenosine Deaminase Acting on the RNA 1 Gene Homozygous Mutations.

Authors:  Lingjuan Liu; Lu Zhang; Peng Huang; Jie Xiong; Yangyang Xiao; Cheng Wang; Dingan Mao; Liqun Liu
Journal:  Front Pediatr       Date:  2022-06-27       Impact factor: 3.569

2.  The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS.

Authors:  Kader Cetin Gedik; Lovro Lamot; Micol Romano; Erkan Demirkaya; David Piskin; Sofia Torreggiani; Laura A Adang; Thais Armangue; Kathe Barchus; Devon R Cordova; Yanick J Crow; Russell C Dale; Karen L Durrant; Despina Eleftheriou; Elisa M Fazzi; Marco Gattorno; Francesco Gavazzi; Eric P Hanson; Min Ae Lee-Kirsch; Gina A Montealegre Sanchez; Bénédicte Neven; Simona Orcesi; Seza Ozen; M Cecilia Poli; Elliot Schumacher; Davide Tonduti; Katsiaryna Uss; Daniel Aletaha; Brian M Feldman; Adeline Vanderver; Paul A Brogan; Raphaela Goldbach-Mansky
Journal:  Ann Rheum Dis       Date:  2022-01-27       Impact factor: 27.973

Review 3.  To protect and modify double-stranded RNA - the critical roles of ADARs in development, immunity and oncogenesis.

Authors:  Emily A Erdmann; Ananya Mahapatra; Priyanka Mukherjee; Boyoon Yang; Heather A Hundley
Journal:  Crit Rev Biochem Mol Biol       Date:  2020-12-27       Impact factor: 8.250

Review 4.  Emerging roles of the RNA modifications N6-methyladenosine and adenosine-to-inosine in cardiovascular diseases.

Authors:  Vilbert Sikorski; Antti Vento; Esko Kankuri
Journal:  Mol Ther Nucleic Acids       Date:  2022-07-20       Impact factor: 10.183

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.